Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomised, double-blind, placebo-controlled phase I trial evaluating the safety, tolerability and pharmacokinetics of single ascending doses of APD 371 in healthy adult volunteers

Trial Profile

Randomised, double-blind, placebo-controlled phase I trial evaluating the safety, tolerability and pharmacokinetics of single ascending doses of APD 371 in healthy adult volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 07 Feb 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Olorinab (Primary)
  • Indications Pain
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 07 Feb 2019 According to an Arena Pharmaceuticals media release, data from the study will be presented at Crohn's & Colitis Congress 2019.
    • 29 Apr 2015 Status changed from recruiting to completed, as reported in an Arena Pharmaceuticals media release.
    • 29 Apr 2015 Positive results published in an Arena Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top